<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783965</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000618240</org_study_id>
    <secondary_id>5R01CA109584-05</secondary_id>
    <secondary_id>U19CA081888</secondary_id>
    <nct_id>NCT00783965</nct_id>
  </id_info>
  <brief_title>Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back</brief_title>
  <official_title>A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCSF Benioff Children's Hospital Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UCSF Benioff Children's Hospital Oakland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is comparing two different schedules of topical&#xD;
      tazarotene and topical placebo to see how well they work in treating patients with basal cell&#xD;
      skin cancer and basal cell nevus syndrome on the chest.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To expand and refine chemopreventive strategies in individuals with basal cell nevus&#xD;
           syndrome (BCNS) on the chest and back, who are at high risk for the development of basal&#xD;
           cell carcinomas (BCCs).&#xD;
&#xD;
        -  To determine whether tazarotene 0.1% cream applied to the chest for two years will&#xD;
           reduce the numbers of basal cell carcinomas (BCCs) observed, as compared to the number&#xD;
           expected, based on changes in BCC numbers observed during months 0-12.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare the difference in total BCC burden (measured as the total lesion surface&#xD;
           area) between chest and back over various time points and aggregated intervals of&#xD;
           interest.&#xD;
&#xD;
        -  To determine whether there are any detectable wash-in or wash-out periods for the&#xD;
           tazarotene effects.&#xD;
&#xD;
        -  Explore the use of a random effects model for longitudinal analysis of total lesions&#xD;
           over time.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized into 1 of 2 arms.&#xD;
&#xD;
        -  Arm I: Patients apply 0.1% tazarotene cream on months 0-12 and vehicle (placebo) on&#xD;
           months 13-36 once daily to the chest in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients apply vehicle (placebo) on months 0-12 and 0.1% tazarotene cream on&#xD;
           months 13-36 once daily to the chest in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      Treated chest and untreated back is evaluated at 3 month intervals for 36 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Reduction in the Observed Numbers of Basal Cell Carcinomas ≥ 9 mm² in Diameter</measure>
    <time_frame>Baseline and 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Parameters of Safety: Number of Participants With Adverse Events According to NCI CTCAE v3.0</measure>
    <time_frame>Baseline and 36 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Skin Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients apply 0.1% tazarotene cream on months 0-12 and vehicle (placebo) on months 13-36 once daily to the chest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients apply, vehicle (placebo) on months 0-12 and 0.1% tazarotene cream on months 13-36 once daily to the chest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tazarotene</intervention_name>
    <description>Applied to the skin</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>tazorac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Applied to the skin</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        List of Inclusion Criteria:&#xD;
&#xD;
          1. Study subjects must have at least one basal cell carcinoma ≥ 3mm in diameter (target&#xD;
             lesion) on any area of the skin except the face, chest, and back (and not impinging on&#xD;
             vital sites) diagnosed clinically by a Study Investigator at the baseline visit.&#xD;
&#xD;
          2. Study subjects must meet diagnostic criteria for basal cell nevus syndrome including&#xD;
             major criterion #1 plus one additional major criterion or two of the minor criteria&#xD;
             outlined in Table I. A first degree relative would satisfy BCNS diagnostic criteria&#xD;
             with any two major criteria or any single major plus two minor criteria.&#xD;
&#xD;
        Table I. BCNS Diagnostic Criteria&#xD;
&#xD;
        Major criteria&#xD;
&#xD;
          1. More than 2 BCCs or one under the age of 20 years&#xD;
&#xD;
          2. Odontogenic keratocysts of the jaw proven by histology&#xD;
&#xD;
          3. Three or more palmar and/or plantar pits&#xD;
&#xD;
          4. Bilamellar calcification of the falx cerebri (if less than 20 years old)&#xD;
&#xD;
          5. Fused, bifid, or markedly splayed ribs.&#xD;
&#xD;
          6. First degree relative with basal cell nevus syndrome (BCNS)&#xD;
&#xD;
          7. PTCH1 gene mutation in normal tissue*&#xD;
&#xD;
        Minor criteria&#xD;
&#xD;
          1. Macrocephaly determined after adjustment for height&#xD;
&#xD;
          2. Congenital malformations: cleft lip or palate, frontal bossing, &quot;coarse face.&quot;&#xD;
&#xD;
          3. Skeletal abnormalities: Sprengel deformity, marked pectus deformity&#xD;
&#xD;
          4. Radiological abnormalities: bridging of the sella turcica, vertebral anomalies such as&#xD;
             hemivertebrae, fusion or elongation of the vertebral bodies.&#xD;
&#xD;
          5. Ovarian fibroma&#xD;
&#xD;
          6. Medulloblastoma&#xD;
&#xD;
        3.The subject is from 18-75 years of age, inclusive.&#xD;
&#xD;
        4. If the subject is female and of child-bearing potential (women are considered not of&#xD;
        childbearing potential if they are at least 2 years post-menopausal and/or surgically&#xD;
        sterile), she:&#xD;
&#xD;
        i. has been using adequate contraception (abstinence, IUD, birth control pills, or&#xD;
        spermicidal gel with diaphragm or condom) since her last menses and will use adequate&#xD;
        contraception during the study, and ii. is not lactating, and iii. has documented one&#xD;
        negative serum pregnancy test within 14 days prior to study entry.&#xD;
&#xD;
        5. The subject is willing to abstain from application of non-study topical medications to&#xD;
        the skin of the face for the duration of the study, including prescription and over the&#xD;
        counter preparations.&#xD;
&#xD;
        6. The subject is willing not to have targeted BCCs treated by their PSCP unless the BCCs&#xD;
        are documented by Study Investigators, preferably on two separate visits, except when the&#xD;
        PSCP believes that delay in treatment potentially might compromise the health of the&#xD;
        subject.&#xD;
&#xD;
        List of Exclusion Criteria:&#xD;
&#xD;
          1. The subject has used topical or systemic therapies that might interfere with the&#xD;
             evaluation of the study medication during the study.&#xD;
&#xD;
          2. The subject has a history of hypersensitivity to any of the ingredients in the study&#xD;
             medication formulations.&#xD;
&#xD;
          3. The subject is unable to return for follow-up tests.&#xD;
&#xD;
          4. The subject has uncontrolled systemic disease, including known HIV positive patients.&#xD;
&#xD;
          5. The subject has a history of other skin conditions or significant illness that would&#xD;
             interfere with evaluation of the study medication.&#xD;
&#xD;
          6. Any condition or situation which in the Investigator's opinion may put the subject at&#xD;
             significant risk, could confound the study results, or could interfere significantly&#xD;
             with the subject's participation in the study.&#xD;
&#xD;
          7. The subject has a history of invasive cancer within the past five years excluding&#xD;
             non-melanoma skin cancer, Stage I cervical cancer, or CLL Stage 0.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ervin Epstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Benioff Children's Hospital Oakland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David R. Bickers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Oakland Research Institute</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609-1693</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Oakland Research Institiute</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>October 31, 2008</study_first_submitted>
  <study_first_submitted_qc>October 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2008</study_first_posted>
  <results_first_submitted>July 31, 2013</results_first_submitted>
  <results_first_submitted_qc>January 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2016</results_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nevoid basal cell carcinoma syndrome</keyword>
  <keyword>basal cell carcinoma of the skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Basal Cell Nevus Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazarotene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I</title>
          <description>0.1% tazarotene cream first, then placebo</description>
        </group>
        <group group_id="P2">
          <title>Arm II</title>
          <description>Vehicle (placebo) first, then 0.1% tazarotene cream</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (12 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (24 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients apply 0.1% tazarotene cream on months 0-12 and vehicle (placebo) on months 13-36 once daily to the chest.&#xD;
placebo : Applied to the skin&#xD;
tazarotene : Applied to the skin</description>
        </group>
        <group group_id="B2">
          <title>Arm II</title>
          <description>Patients apply, vehicle (placebo) on months 0-12 and 0.1% tazarotene cream on months 13-36 once daily to the chest.&#xD;
placebo : Applied to the skin&#xD;
tazarotene : Applied to the skin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="7"/>
                    <measurement group_id="B2" value="51" spread="13"/>
                    <measurement group_id="B3" value="53" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reduction in the Observed Numbers of Basal Cell Carcinomas ≥ 9 mm² in Diameter</title>
        <time_frame>Baseline and 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients apply 0.1% tazarotene cream on months 0-12 and vehicle (placebo) on months 13-36 once daily to the chest.&#xD;
placebo : Applied to the skin&#xD;
tazarotene : Applied to the skin</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients apply, vehicle (placebo) on months 0-12 and 0.1% tazarotene cream on months 13-36 once daily to the chest.&#xD;
placebo : Applied to the skin&#xD;
tazarotene : Applied to the skin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reduction in the Observed Numbers of Basal Cell Carcinomas ≥ 9 mm² in Diameter</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Parameters of Safety: Number of Participants With Adverse Events According to NCI CTCAE v3.0</title>
        <time_frame>Baseline and 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients apply 0.1% tazarotene cream on months 0-12 and vehicle (placebo) on months 13-36 once daily to the chest.&#xD;
placebo : Applied to the skin&#xD;
tazarotene : Applied to the skin</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients apply, vehicle (placebo) on months 0-12 and 0.1% tazarotene cream on months 13-36 once daily to the chest.&#xD;
placebo : Applied to the skin&#xD;
tazarotene : Applied to the skin</description>
          </group>
        </group_list>
        <measure>
          <title>Parameters of Safety: Number of Participants With Adverse Events According to NCI CTCAE v3.0</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients apply 0.1% tazarotene cream on months 0-12 and vehicle (placebo) on months 13-36 once daily to the chest.&#xD;
placebo : Applied to the skin&#xD;
tazarotene : Applied to the skin</description>
        </group>
        <group group_id="E2">
          <title>Arm II</title>
          <description>Patients apply, vehicle (placebo) on months 0-12 and 0.1% tazarotene cream on months 13-36 once daily to the chest.&#xD;
placebo : Applied to the skin&#xD;
tazarotene : Applied to the skin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>cellulitis and maxillary sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>prostate cancer diagnosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Peeling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Non-compliance and large drop-out rates leading to small numbers of data analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Raj Prasad</name_or_title>
      <organization>ChildrensHRCOakland</organization>
      <phone>510-450-7602 ext 7602</phone>
      <email>rprasad@chori.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

